NSEChange in Management28 Sept 2026 · 28 Sept 2026, 08:51 pm
Change in Management
Bliss GVS Pharma Limited · BLISSGVS
✦ AI SummaryMgmt Change
Bliss GVS Pharma Limited has informed the Exchange about change in Management pursuant to the Change in Control of the Company. The Board of Directors has appointed three new directors and noted the resignation of the Managing Director.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk4/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bliss GVS Pharma Limited has informed the Exchange about change in Management pursuant to the Change in Control of the Company.
Attachments (1)
📄pdf
Download →
BLISSGVS_28092026205124_Outcome___BM___Bliss_GVS___1_Board_Meeting.pdf
View document text
September 28, 2026
To To
The Manager, Listing Department The General Manager, Listing Department
National Stock Exchange of India Ltd. BSE Limited
Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers,
Bandra-Kurla Complex, Bandra (East), Dalal Street,
Mumbai- 400 051 Mumbai- 400 001
Symbol: BLISSGVS Scrip Code: 506197
Dear Sir/Madam,
Subject: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").
Ref: Disclosure under Regulations 30 of the SEBI Listing Obligations.
Pursuant to Regulations 30 read with Schedule III of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform
you that the Board of Directors of the Company, at its meeting held today i.e. September 28,
2026, has, inter alia, considered and approved/noted the following matters in relation to the
consummation of the transaction contemplated in the share purchase agreement dated May
23, 2026 (“SPA”) entered into amongst Anupam Rasayan India Limited (“Purchaser”), the
Sellers (as defined in the SPA), including Mr. S. N. Kamath as Seller 1 (as defined in the SPA),
read with the Deed of Adherence dated July 17, 2026 executed between Mates Visa
Consultancy Private Limited (“PAC”) and the Purchaser whereby the Purchaser had assigned
its rights under the SPA to PAC (collectively, “Transaction Documents”):
1) Change in Control and Promoter Status:
The PAC has completed the acquisition of 5,09,84,595 equity shares of Bliss GVS Pharma
Limited (“Company”), representing 47.95% of the equity share capital of the Company as
on date of the meeting, pursuant to the consummation of the transaction contemplated in
the SPA on September 28, 2026. Following the aforesaid acquisition, and together with 1669
equity shares of the Company acquired by the Purchaser under the Open Offer, the
Purchaser and the PAC collectively hold an aggregate of 5,09,86,264 equity shares of the
Company, representing 47.95% of the equity share capital of the Company.
Accordingly, with effect from September 28, 2026, Anupam Rasayan India Limited, along
with Mates Visa Consultancy Private Limited, being the Purchaser and PAC, respectively,
have acquired control of the Company pursuant to the completion of the Open Offer (as
defined in the SPA) and the consummation of the transaction contemplated under the SPA
and therefore have become the ‘Promoters’ of the Company in accordance with the
applicable provisions of the SEBI Listing Regulations and the SEBI (Substantial Acquisition
of Shares and Takeovers) Regulations, 2011.
2) Appointment of Directors:
a) Appointment of Mr. Hetul Krishnakant Mehta [DIN:01650314] as an Additional
Director of the Company in the capacity of a Non-Executive Non-Independent Director
with effect from September 28, 2026.
b) Appointment of Mr. Amar Dilip Shah [DIN: 00214357] as an Additional Director of the
Company in the capacity of a Non-Executive Non-Independent Director with effect
from September 28, 2026.
c) Appointment of Mr. Pramod Badrinarayan Kasat [DIN: 00819790] as an Additional
Director of the Company in the capacity of a Non-Executive Non-Independent Director
with effect from September 28, 2026.
The brief profile and other requisite details pertaining to the aforesaid appointment are
enclosed as “Annexure – 1”, “Annexure – 2” and “Annexure – 3”, respectively.
3) Resignation of Mr. Narsimha Shibroor Kamath (DIN: 00140593) from the position of
Managing Director of the Company and other positions:
The Board has noted and taken on record the resignation of Mr. Narsimha Shibroor Kamath
(“Mr. Kamath”) from the position of Managing Director of the Company with effect from
September 28, 2026.
The resignation letter received from Mr. Kamath is enclosed herewith.
The requisite details as required under Regulation 30 of the SEBI Listing Regulations read
with Schedule III thereof SEBI Master Circular No. HO/49/14/14(7)2025-CFD-
POD2/I/3762 /2026 dated January 30, 2026 attached as “Annexure – 4”.
4) Approval of Postal Ballot Notice:
Approved the draft Postal Ballot Notice seeking approval of the Members of the Company
for the appointment of Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah and Mr.
Pramod Badrinarayan Kasat as Non-Executive Non-Independent Directors of the
Company. The Postal Ballot Notice will be dispatched to the Members of the Company in
accordance with the applicable provisions of the Companies Act, 2013, the rules made
thereunder and the SEBI Listing Regulations.
The meeting of the Board of Directors commenced at 6:41 p.m. and concluded at 6:57 p.m.
Kindly take the above information on your record and acknowledge.
Thanking you,
Yours Faithfully,
For Bliss GVS Pharma Limited
Aditi Bhatt
Company Secretary & Compliance Officer
Encl.: As above
“Annexure – 1”
No. Particulars Change
1 Name of the Person Mr. Hetul Krishnakant Mehta
2 Reason for change viz. appointment, Appointment
reappointment, resignation, removal,
death or otherwise
3 Date of appointment / cessation & September 28, 2026
Term of appointment
4 Brief Profile Mr. Hetul K. Mehta is an entrepreneur with
over 30 years of experience in the
pharmaceutical industry, particularly in
bulk drug manufacturing. He is the
Managing Director of Praveen Laboratories
Pvt. Ltd., which he co-founded in 1995. He
has extensive experience in pharmaceutical
manufacturing, regulatory compliance,
quality assurance and strategic business
management. He has served as an
Independent Director of Anupam Rasayan
India Limited from 2021 to 2024 and
chaired various Board Committees. He is
also associated with Globe Envirocare Ltd.
and Advanced Diabetes Centre Pvt. Ltd.
He has been actively involved with
industry bodies including CII and the
South Gujarat Chamber of Commerce and
Industry. He holds a degree in Chemical
Engineering from Bharati Vidyapeeth,
Pune.
5 Disclosure of relationships between No relation with any of the directors of the
directors Company.
6 Other Confirmation Mr. Hetul Krishnakant Mehta is not
debarred or disqualified from being
appointed or continuing as a Director of the
Company by the SEBI, MCA or any other
statutory or regulatory authority order or
directions.
“Annexure – 2”
No. Particulars Change
1 Name of the Person Mr. Amar Dilip Shah
2 Reason for change viz. appointment, Appointment
reappointment, resignation, removal,
death or otherwise
3 Date of appointment / cessation & September 28, 2026
Term of appointment
4 Brief Profile Mr. Amar Dilip Shah is an experienced
business professional with extensive
experience in sales, marketing, business
development and strategic planning. He is
currently associated with Siyaram Silk
Mills Limited, where he is responsible for
sales across Japan, India and USA and also
oversees the P&L of a greenfield garment
manufacturing unit. He has significant
experience in the apparel and textile
industry, including working with high
street brands and garment converters. He
previously served as Working Director of
Futuristic Concepts Media Limited for over
22 years. He has also been associated with
Web Werks India Pvt. Ltd., where he
handled sales, marketing and business
operations. He has expertise in establishing
new ventures, operational management,
technology implementation and business
expansion. He has also undertaken
programmes in renewable energy,
international energy policy and project
management.
5 Disclosure of relationships between No relation with any of the directors of the
directors Company.
6 Other Confirmation Mr. Amar Dilip Shah is not debarred or
disqualified from being appointed or
continuing as a Director of the Company by
the SEBI, MCA or any other statutory or
regulatory authority order or directions.
“Annexure – 3”
No. Particulars Change
1 Name of the Person Mr. Pramod Badrinarayan Kasat
2 Reason for change viz. appointment, Appointment
reappointment, resignation, removal,
death or otherwise
3 Date of appointment / cessat
[Showing first 8,000 characters — download PDF for full document]